MALVERN, Pa. & PRINCETON, N.J.--(BUSINESS WIRE)--Marillion Pharmaceuticals Inc. and Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business and part of the Bracco Group, announced today that the two companies have entered into a license agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco’s 177Lu-AMBA for the treatment of hormone-resistant prostate and advanced (metastatic) breast cancers.
